Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA
Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA.
Inj Prev. 2021 Aug;27(4):395-398. doi: 10.1136/injuryprev-2020-043968. Epub 2021 Feb 3.
Reports from active drug users state that xylazine, the veterinary tranquilliser, has been increasing in the illicit drug supply in Philadelphia. To describe trends and characteristics of unintentional deaths from heroin and/or fentanyl overdose with xylazine detections occurring in Philadelphia, Pennsylvania, the Philadelphia Department of Public Health analysed data on deaths from unintentional heroin and/or fentanyl overdose from the Philadelphia Medical Examiner's Office over a 10-year period (2010-2019). Xylazine went from being detected in less than 2% cases of fatal heroin and/or fentanyl overdose between 2010 and 2015 to 262 (31%) of the 858 fatal heroin and/or fentanyl overdose cases in 2019. Currently, information is limited on the presence of xylazine in continental United States. Xylazine's association with adverse outcomes in other locations indicates that potential health consequences should also be monitored in the USA. Whenever possible, jurisdictions should consistently test for xylazine.
来自活跃吸毒者的报告称,兽医镇静剂苯环己哌啶在费城的非法毒品供应中不断增加。为了描述宾夕法尼亚州费城发生的海洛因和/或芬太尼过量且检测到苯环己哌啶的非故意死亡的趋势和特征,费城公共卫生部分析了费城法医办公室在 10 年期间(2010-2019 年)因非故意海洛因和/或芬太尼过量导致的死亡数据。苯环己哌啶的检出率从 2010 年至 2015 年期间在致命海洛因和/或芬太尼过量的不到 2%的病例中下降到 2019 年 858 例致命海洛因和/或芬太尼过量病例中的 262 例(31%)。目前,关于苯环己哌啶在美国大陆存在的信息有限。苯环己哌啶在其他地方与不良后果的关联表明,美国也应该监测潜在的健康后果。只要有可能,司法管辖区就应该始终对苯环己哌啶进行检测。